Hosted on MSN7h
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
FDA approves tablet form of Evrysdi for spinal muscular atrophy
The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a ...
The Lancet1d
Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies
Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...